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http://www.jbiomedsci.com/content/20/1/8RESEARCH Open AccessRecombinant salmonella-based 4-1BBL vaccine
enhances T cell immunity and inhibits the
development of colorectal cancer in rats: in vivo
effects of vaccine containing 4-1BBL
Jianxin Ye1†, Ling Li1†, Yuanting Zhang1, Xueguang Zhang2, Daming Ren3 and Weichang Chen1*Abstract
Background: Immunotherapy with vaccines is attractive for the treatment of cancer. This study is aimed at
determining the effect of recombinant Salmonella (SL3261)-based 4-1BB ligand (4-1BBL) vaccine on the
development of colorectal cancers and the potential immune mechanisms in rats.
Results: In comparison with that in the PBS group, similar levels of 4-1BBL expression, the frequency of T cells,
IFN-γ responses, and comparable numbers of tumors were detected in the SL3261 and SL3261C groups of rats. In
contrast, significantly fewer numbers of tumors, increased levels of 4-1BBL expression in the spleens and colorectal
tissues, higher frequency of peripheral blood and splenic CD3+CD25+ T cells, and stronger splenic T cell IFN-γ
responses were detected in the SL3261R group of rats.
Conclusion: Our results indicated that vaccination with recombinant attenuated Salmonella harboring the 4-1BBL
gene efficiently enhanced T cell immunity and inhibited the development of carcinogen-induced colorectal cancers
in rats.
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Immunotherapy represents an attractive strategy for the
prevention of tumor recurrence and the control of cancer
growth [1,2]. Immunotherapy can induce antigen-specific
T cell responses that can inhibit the growth of tumors.
Effective activation of naïve T cells depends on TCR
engagement and efficient co-stimulation [3,4]. The 4-1BB
ligand (L) is expressed on antigen-presenting cells (APC),
and can interact with 4-1BB on activated T cells, co-
stimulating T cell cytokine production and proliferation
[5-8], and prolonging T cell survival [7,9]. Therefore, 4-1BB
and 4-1BBL are important regulators of T cell immunity.
Previous studies have shown that vaccination with an-
tigen peptide linked with 4-1BBL enhances dendritic cell
activation and antigen uptake and promotes CD8+ T cell* Correspondence: weichangchen@126.com
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reproduction in any medium, provided the oreffector/memory responses [10,11]. Similarly, the admin-
istration of both 4-1BBL and a HPV-specific E7 peptide
or survivin protein eliminates E7-expressing TC-1
cervical cancer or survivin-expressing 3LL lung tumors
in vivo [10,11]. Zhang et al. [12] reported that vaccin-
ation with natural CD137 ligand, is more efficient
and less toxic side effects in inducing colorectal tumor
regression in mice, as compared with treatment with
anti-4-1BB agonist antibodies. In addition, our previous
study has found that vaccination with a recombinant
Salmonella-based 4-1BBL vaccine efficiently enhances
T cell immunity in rats [13]. However, whether and
how vaccination with a recombinant Salmonella-based
4-1BBL vaccine inhibits the development of colorectal
tumors have not been fully illustrated.
In this present study, we investigated the effects of vac-
cination with a recombinant Salmonella-based 4-1BBL
vaccine on the development of 1, 2-dimethylhydrazine
(DMH)-induced colorectal tumors in rats. Our resultsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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based 4-1BBL vaccine effectively transferred the 4-1BBL
gene into APCs and up-regulated 4-1BBL expression in
APCs. Moreover, the up-regulation of 4-1BBL expression
in APCs induced vigorous T cell immunity and inhibited
the development of colorectal cancer in rats.
Methods
Bacteria
Salmonella typhimurium LB5000 and the attenuated
Salmonella enterica serova typhimurium SL3261 were
generously provided by Professor Stocker from Stanford
University, USA. Plasmid pIRES2-EGFP was purchased
from BD Biosciences Clontech (Palo Alto, CA, USA).
The pIRES2-EGFP-transformed SL3261C or pIRES2-
EGFP-4-1BBL-transformed SL3261R were generated, as
previously described [13].
Animals
A total of 20 male Sprague Dawley (SD) rats at 6–8 weeks
of age were obtained from the Center of Experimental
Animal of Soochow University. Rats were housed in
a specific-pathogen-free (SPF) facility in 12-h light/dark
cycle at 50 ± 10% humidity and 21 ± 2°C with free access
to water and food. The body weights of individual rats
were measured weekly. The experimental protocols were
approved by the Ethics Committee of the First Affiliated
Hospital of Soochow University.
Establishment of rat model of colorectal tumor
Individual animals were administered subcutaneously
with 20 mg/kg 1, 2-dimethylhydrazine (DMH, Sigma, St.
Louis, USA) weekly for 20 consecutive weeks. Fourteen
weeks after the first DMH administration, the rats were
randomized and gavaged with 2 ml PBS, PBS containing
2 × 109 SL3261, the pIRES2-EGFP-transformed SL3261,
or the pIRES2-EGFP-4-1BBL-transformed SL3261 every
two weeks for three times as the control, SL3261,
SL3261C, or SL3261R group, respectively. At 21 weeks
post the first DMH injection, the rats were anesthetized
and their blood samples were collected and sacrificed.
Their spleens were dissected, and a portion of the spleen
from each rat was used for immunofluorescent staining.
Gross and histological examination
The entire colorectal (from the cecum to the anus)
tissues of individual rats were removed, washed thor-
oughly with ice-cold saline, cut longitudinally, and laid
flat on a board. The numbers of tumors were counted in
a blinded manner. The disease stages of colorectal
cancers were evaluated by Duke’s stage system [14] with
minor modifications. Briefly, Stage A: tumors only in the
mucosa; Stage B-C, tumors invading into muscularispropria, but without distant metastasis; and Stage D:
tumor with distant metastasis.
Flow cytometric analysis
Peripheral blood mononuclear cells (PBMC) were isolated
either at 16 weeks or 21 weeks post the initial DMH
administration and splenic monnocnulear cells were
prepared at 21 weeks post the initial DMH administration
by Ficoll-paque density gradient centrifugation. The fre-
quency of different subsets of T cells was characterized
by flow cytometry. Briefly, 1 × 105 cells were stained with
anti-CD3-PE, anti-CD3-FITC, anti-CD8-FITC, anti-CD4-
FITC, and anti-CD25-PE antibodies (Ebioscience), and
after washing, the cells were subjected to flow cytometry
and analyzed by FlowJo software.
Reverse transcription-polymerase chain reaction (RT-PCR)
The relative levels of GFP mRNA transcripts in sple-
nocytes were determined by RT-PCR. Briefly, total RNA
was extracted from individual splenic mononuclear cell
samples and reversely transcribed into cDNA using a
specific kit TakaRa (Dalian, China), according to the
manufacturers’ instruction. The sequences of primers
were forward 50-CACAAGTTCAGCGTGTCCG-30 and
reverse 50-CTCGATGCGGTTCACCAG-30 for GFP; for-
ward 50-GAGGGAAATCGTGCGTGAC-30 and reverse
50-TAGAAGCATTTGCGGTGC-30 for β-actin. PCR am-
plification was performed in duplicate at 94°C for 5 min
and subjected to 33 cycles of 94°C for 30 s, 49°C for 30 s,
and 72ºC for 35 s, followed by 72°C for 10 min.
Immunofluorescence
The levels of 4-1BBL and GFP expression were detected
by immunofluorescence, as previously described [13]. In
brief, the frozen spleen and colorectal tissue sections
were fixed in Acetone and stained with goat anti-
4-1BBL antibodies (CD137L, Santa Cruz Biotech, Santa
Cruz, USA) and rabbit anti-GFP antibodies, respect-
ively. After being washed, the bound antibodies were
detected with donkey anti-goat-CY3 and goat anti-
rabbit-FITC antibodies (Beyotime Institute of Biotech-
nology, Haimen, Jiangsu, China). Subsequently, the
sections were mounted and examined under a confocal
microscope (Leica, Germany).
Enzyme-linked immunosorbent assay (ELISA)
Splenic monnocnulear cells were prepared at 21 weeks
post the initial DMH administration by Ficoll-paque
density gradient centrifugation. Splenic mononuclear
cells (2.5 × 105 cells/ml) were stimulated in triplicate
with 10 μg/ml of PHA-P (Sigma) in RPMI1640 (GIBCO)
medium containing 10% FCS and 2 μg/ml of Ciprobay
(HealthCare, AG) for 72 hours. The supernatants of
cultured cells were harvested and the concentrations of
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using a rat IFN-γ detection kit, according to the
manufacturers’ instruction (Jingmei Biotech, Shenzhen,
China).Statistical analysis
Data were expressed as the means ± SD. The difference
among different groups was assessed by analysis of vari-
ance (ANOVA) and the difference between two groups
was assessed by Student’s t-test. A P value of < 0.05 was
considered statistically significant.Results
Expression of reporter gene GFP and 4-1BBL protein
We first evaluated the reporter gene GFP mRNA tran-
scription in splenocytes of different groups of rats using
RT-PCR technique at 21-week post the initial DMH ad-
ministration. We detected GFP mRNA transcripts in the
spenocytes from the rats vaccinated with SL3261C or
SL3261R (recombinant attenuated Salmonella typhimu-
rium carrying pIRES2-EGFP or pIRES2-EGFP-4-1BBL
plasmids), but not in the control and SL3261-vaccinated
rats (Figure 1). Further immunofluorescent analysis re-
vealed that GFP protein expression was detected in the
spleen and colorectal tissues from the SL3261C- and
SL3261R-vaccinated rats (Figures 2 and 3). In addition,
analysis of the 4-1BBL expression revealed that the in-
tensity of anti-4-1BBL staining increased in the spleen
and colorectal tissues from the SL3261R-vaccinated rats.
These observations indicated that vaccination with the
SL3261R effectively enhanced 4-1BBL expression in these
tissues of rats.Figure 1 RT-PCR analysis of GFP mRNA transcripts in splenocytes of t
21 weeks, the rats were sacrificed and their splenocytes were isolated. Sub
groups of rats were elevaluated by RT-PCR. β-actin was used as an internal
experiments. Lane M, DNA marker; 1, PBS; 2, SL3261; 3, SL3261C; 4, SL3261RVaccination with the SL3261R reduces the numbers of
colorectal tumors in rats
Following the induction of colorectal tumors, one out of
20 rats died at 20 weeks post the initial DMH treatment.
Characterization of animals indicated that a large amount
of bloody ascites was found in the rats. A great number of
tumor nodules varying in size were observed in the mes-
entery and posterior peritoneum. The rigor of the colorec-
tal rectal wall appeared. A total of 18 adenocarcinoma
were identified by histological examination using H & E
staining and visualized in the entire colorectal of the dead
rats (data not shown). In addition, the numbers of tumors
at 21 weeks post DMH treatment were 18.2 ± 4.7 in the
PBS group; 12.8 ± 4.5 in the SL3261-treated group; 12.2 ±
4.4 in the SL3261C-treated group; and 9.4 ± 4.3 in the
SL3261R-treated group (Figure 4A). The number of
tumors in the SL3261R-treated group of rats was signifi-
cantly less than that in the PBS group. In addition, we
found that most of the tumors in the PBS group of rats
were at Dukes’ stage D (stage B-C, 1; Stage D, 4), while
most tumors in the SL3261 and SL3261C groups were at
stage B-C (SL3261: stage A, 1; stage B-C, 2; Stage D, 2;
SL3261C: stage B-C, 4; stage D, 1). However, the tumors
in the SL3261R group of rats were at stage A-C (Stage A,
2; Stage B-C, 2) (Table 1). Moreover, there was no signifi-
cant difference in the rat body weights among the four
groups, although slightly increased body weights were
observed in the SL3261R-vaccinated group of rats 16 -
weeks after DMH application (Figure 4B).
T cell phenotypes
To understand the anti-tumor effect, the frequency of
different subsets of peripheral and splenic T cells washe rats from different groups. Following administration of DMH for
sequently, the GFP mRNA transcripts in spelnocytes from different
control. Data shown are representative images from three separate
; 5, Negative control (RNA without reverse transcription).
Figure 2 Immunofuorescent analysis of 4-1BBL expression on rat spleens. The expression of GFP and 4-1BBL in the spleens of different
groups of rats was characterized by immunofuorescent assays using anti-4-1BBL (red) and anti-GFP (green) antibodies and examining under a
confocal microscopy. Data shown are representative images of different groups of rats (n = 4 for the PBS group, n = 5 for other groups) from
three separate experiments. (A) The PBS group; (B) The SL3261 group; (C) The SL3261C group; (D) The SL3261R group.
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Figure 3 Immunofuorescent analysis of 4-1BBL expression on the colorectal tumor tissues of rats. The expression of GFP and 4-1BBL in
the colorectal tumor tissues from different groups of rats was characterized by immunofuorescent assays using anti-4-1BBL (red) and anti-GFP
(green) antibodies and examining under a confocal microscopy. Data shown are representative images of different groups of rats (n = 4 for the
PBS group, n = 5 for other groups) from three separate experiments. (A) The PBS group; (B) The SL3261 group; (C) The SL3261C group; (D) The
SL3261R group.
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Figure 4 The body weights and the number of tumors in
different groups of rats. Following induction of colorectal tumors,
the body weights of individual rats were measured longitudinally
and the numbers of colorectal tumors in individual rats at 21 weeks
post the induction were examined in a blinded manner. Data are
expressed as the mean or mean ± SD of different groups of rats
(n = 5 per group). (A) The numbers of tumors. (B) The body weights
of animals. *P < 0.05 SL3261R vs. PBS.
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the initial DMH administration. We found that the fre-
quency of peripheral blood CD3+CD8+ and CD3+CD25+
T cells, but not the total CD3+ and CD3+CD4+ T cells, in
the SL3261R group was significantly higher than that in
the PBS control (P < 0.05) (Figure 5A). No significant dif-
ference was found in the number of CD3+, CD3+CD4+Table 1 Analysis of tumor staging in rats from different
experimental groups
Groups Negative Stage A Stage B-C Stage D
PBS 0 0 1 4
SL3261 0 1 2 2
SL3261C 0 0 4 1
SL3261R 1 2 2 0
The number of animals in Dukes Stage A, Stage B-C or Stage D was listed.and CD3+CD8+ T cells of peripheral blood and splenic
T cells among PBS control, SL3261 and SL3261C groups
21 weeks after the initial DMH administration (P > 0.05).
But CD3+CD25+ T cells in the SL3261R group was signifi-
cantly higher than that in the other groups (P < 0.05)
(Figure 5B-C).
Vaccination with the SL3261R enhances splenic IFN-γ
responses
The concentrations of IFN-γ in the cultured supernatants
of splenocytes stimulated with PHA from individual
groups of rats were analyzed by ELISA. As shown in
Figure 6, the levels of IFN-γ were comparable among the
PBS, SL3261, and SL3261C-treated rats. In contrast, the
concentrations of IFN-γ in the cultured splenocytes from
the SL3261R-vaccinated rats were significantly higher than
that in the other groups of rats (P < 0.01). However, no
significant difference was detected among PBS, SL3261,
and SL3261C groups (P > 0.05).
Discussion
The 4-1BBL is a type II surface glycoprotein of the tumor
necrosis factor (TNF) superfamily, and is generally
expressed in APCs, such as dendritic cells, macrophages,
and activated B cells [4]. 4-1BBL binds to 4-1BB (also
called CD137), a member of the TNFR superfamily, and
enhances T cell activation [4]. Emerging lines of evidence
shows that activation of 4-1BB by agonistic monoclonal
antibodies (Abs) or over-expressing 4-1BBL enhances
T cell proliferation and cytokine production, up-regulates
anti-apoptotic gene expression and prevents activation-
induced cell death [15-17]. However, systemic adminis-
tration of anti-4-1BB agonistic Abs is unsuccessful in
correcting the defect in response to severe influenza in
4-1BBL-deficient mice, which is possibly because anti-
4-1BB can target many cell types and lead to high levels of
cytokine production and immunopathology [18,19]. A
HIV-1 effective vaccine should induce both antigen-
specific cellular and humoral immunity and DNA vaccine
for inducing 4-1BBL expression is a superior adjuvant to
enhance HIV-specific immunity than anti-4-1BB agonistic
antibody [20]. Based on these findings, our previous study
has shown that recombinant attenuated Salmonella
harboring the 4-1BBL gene can induces high levels of
4-1BBL expression in dendritic and other immune cells
[13]. In the current study, we explored the effect of oral
treatment with a recombinant Salmonella-based 4-1BBL
vaccine on the development of DMH-induced colorectal
cancers in rats and the potential immune mechanisms.
A previous study indicated that abnormal morphology
characterized by accumulation of undifferentiated cells
with pleiomorphic and conspicuous nucleoli in a small
cluster of neighboring crypts was found at 12 weeks post

















Figure 6 ELISA analysis of the concentrations of IFN-γ in the
supernatants of cultured splenocytes. Splenic mononuclear cells
were isolated from individual rats at 21 weeks post induction and
stimulated with PHA for 72 h. The concentrations of IFN-γ in the
supernatants of cultured splenocytes were measured by ELISA. Data
are expressed as the mean ± SD of different groups of rats (n = 4 for
the PBS group, n = 5 for other groups) from three separate
experiments. *P < 0.01 SL3261R vs. PBS; #P < 0.01 SL3261R vs. SL3261;


























































Figure 5 The frequency of different subsets of T cells. Following
induction of colorectal tumors for 16 weeks, peripheral blood
samples were obtained from individual rats and the frequency of
CD3+, CD3 + CD4+, CD3 + CD8+ and CD3 + CD25+ T cells was
characterized by flow cytometry analysis (A). At 21 weeks post
induction, the rats were sacrificed and their peripheral blood (B) and
splenic T cells (C) were characterized by flow cytometry analysis.
Data are expressed as the mean ± SD of different groups of rats
(n = 4 for the PBS group, n = 5 for other groups) from three separate
experiments. *P < 0.05 SL3261R vs. PBS; #P < 0.05 SL3261R vs. SL3261;
^P < 0.05 SL3261R vs. SL3261C.
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Therefore, in this present study, the vaccine administra-
tion was started 14 weeks after the DMH treatment.
Inoculation of recombinant Salmonella appeared to in-
duce more 4-1BBL expression in the spleens and colo-
rectal tumor tissues. Evidentially, we detected the
reporter GFP mRNA transcripts and protein expression
only in the spleens from the SL3261C and SL3261R
groups of rats. Similarly, there was more 4-1BBL expres-
sion in the spleens and colorectal tissues than the other
groups. In this study, we found that SL3261R suppressed
tumor growth as compared with PBS group (P < 0.05).
However, no significant difference was found between
SL3261R group and SL3261 or SL3261C group (P >
0.05), although slightly decreased number of colorectal
tumors was observed in SL3261R group. As Salmonella
can localize to transplantable murine tumors and par-
tially inhibit tumor growth [22], it is possible that the
attenuated Salmonella (SL3261) itself may have anti-
tumor effect. We further staged the colon cancer and
found that most of the tumors in PBS groups were in
late stage (Dukes’ stage D). In SL3261 and SL3261C
groups, tumors were found in middle and late stages
(Dukes’ stage C D), whereas tumors in SL3261R group
were in early and middle stages (Dukes’ stage A B C).
Together, our data extended previous findings and
indicated that recombinant bacteria-based 4-1BBL
vaccines effectively inhibited the development of colo-
rectal cancer [12].
CD3+CD8+ cells are major players of T cell immunity
against tumors [23]. CD25 is the α-chain of IL-2R, which
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cells. Following stimulation by “signal two”, activated
T cells initiate IL-2 expression and secretion, which acts
as an autocrine growth factor because activated T cells ex-
press high-affinity IL-2R. IL-2 exerts its pleiotropic activ-
ities through binding to either dimeric receptor composed
of β-chain IL-2R (CD122) and common cytokine receptor
γ-chain (CD132) or the receptor composed of trimeric IL-
2R. alpha; IL-2Rβ, and common cytokine receptor γ-chain.
CD25 has been considered as a marker of activated
lymphocytes [24,25]. Consistent with our previous results
[13], the number of CD3 +CD8+ and CD3 + CD25+
T cells in peripheral blood obtained from SL3261R group
was increased following induction of colorectal tumors for
16 weeks, when animals were given drug administration
for once (P < 0.05 compared with PBS group). Neverthe-
less, no statistical difference was found between SL3261R
group and SL3261 or SL3261C group (P > 0.05), which
might be due to the short time period of drug administra-
tion and only once vaccine administration. Significant
elevated number of CD3 + CD25+ T cells in peripheral
blood was detected 21 weeks following tumor induction,
when animals were given 3 times of drug administration
in SL3261R group (P < 0.05 compared with all groups),
suggesting the recombinant bacteria-based 4-1BBL vac-
cines can enhance the immune function of tumor-bearing
mice. We did not observe significant difference in the fre-
quency of peripheral blood and splenic CD3+CD8+ T cells
between the SL3261R and other groups of rats at 21 weeks
post DMH treatment, It is possible that CD3+CD8+ T cells
may migrate into the tumors with the progression of
tumorigenesis. More importantly, we detected signifi-
cantly higher levels of splenic IFN-γ responses in the
SL3261R group of rats. Given that IFN-γ is predominantly
secreted by Th1 and cytotoxic CD8+ T cells (the stronger
IFN-γ responses), together with a higher frequency of
activated T cells suggest that the recombinant vaccine
may enhance T cell immunity that inhibits the develop-
ment of colorectal cancers in rats [26].Conclusions
In summary, our data indicated that recombinant
Salmonella-based 4-1BBL vaccine induced 4-1BBL expres-
sion in immune cells and administration of the vaccine ef-
ficiently inhibited the development of DMH-induced
colorectal tumors in rats, accompanied by increasing the
frequency of activated T cells and splenic IFN-γ respon-
ses. Our findings may provide a new basis for the design
of immunotherapies for the intervention of colorectal
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